|
Mr. Young was appointed CEO of CorePharma, LLC in August 2005. CorePharma is a generic pharmaceutical manufacturer of prescription and over-the-counter products. Corepharma also provide contract services to the pharmaceutical industry. Mr. Young served as CEO of NeoPharm from 2004 to 2005. NeoPharm develops innovative technologies to aid patients and their families, and health care providers, in their fight against cancer. In particular, the firm is working to design breakthrough anticancer agents that will enhance the therapeutic benefits while minimizing the side effects of treatment for patients who suffer from rapidly progressing, lethal forms of cancer. Prior to joining NeoPharm, Mr. Young served as Corporate Vice President of Baxter Healthcare Corporate from 2001 to 2004 and as President of Baxter’s Transfusion Therapies Division from 1999 to 2004. The Transfusion Therapies Division develops products and systems for the collection and processing of whole blood and blood components. Mr. Young joined Baxter in 1985 and served in roles of increasing responsibility in sales, marketing and product development within Baxter’s medication delivery business. From 1996 to 1999, he served as President of the Electronic Infusion Division. Baxter International Inc. is a global medical products and services company that, through its subsidiaries, provides critical therapies for people with life-threatening conditions. Mr. Young is a member of the American Pharmaceutical Association and the Board of Directors of St. Louis College of Pharmacy. He was elected to the Board of Lake Forest Graduate School of Management in 2000. Mr. Young received his BS in Microbiology from Northern Illinois University; his BS in Pharmacy from the University of Illinois and his MBA from York College of Pennsylvania. | 